Overview

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability and efficacy in the newly diagnosed subjects with Type 2 diabetes who have glycosylated hemoglobin (HbA1c) value between 7.0 to 10.0 percent (%).
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Metformin